Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors

Gynecologic Oncology

Volumn 113, Issue 2, 2009, Pages 221-227

  Begum, F D ^a   Hogdall E ^b   Kjaer, S K ^a,b   Blaakaer, J ^c   Christensen, I J ^d   Christensen, L ^e   Hogdall C ^a  

^a University of Copenhagen   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d FINSEN LABORATORY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CA125; Ovarian cancer; Risk assessment index; Tetranectin

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; TETRANECTIN;

ARTICLE; BLOOD SAMPLING; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; OVARY TUMOR; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LECTINS, C-TYPE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN DISEASES; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREMENOPAUSE; PREOPERATIVE CARE; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 64149100176     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.01.020     Document Type: Article

References (42)

1. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 1998. CA Cancer J. Clin. 48 (1998) 6-29
2. Qazi F., and McGuire W.P. The treatment of epithelial ovarian cancer. CA Cancer J. Clin. 452 (1995) 88-101
3. Tortolero-Luna G., Mitchekke M.F., and Rhodes-Morris H.E. Epidemiology and screening of ovarian cancer. Obstet. Gynecol. Clin. North Am. 21 (1994) 1-23
4. Einhorn N., Sjövall K., Knapp R.C., Hall P., Scully R.E., Bast Jr. R.C., et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet. Gynecol. 80 (1992) 14-18
5. Jacobs I., Davies A.P., Bridges J., Stabile I., Fay T., Lower A., et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br. Med. J. 306 (1993) 1030-1034
6. Menon U., Skates S.J., Lewis S., Rosenthal A.N., Rufford B., Sibley K., et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23 (2005) 7919-7926
7. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., and Grudzinskas J.G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br. J. Obstet. Gynaecol. 97 (1990) 922-929
8. Tingulstad S., Hagen B., Skjeldestad F.E., Onsrud M., Kiserud T., Halvorsen T., et al. Evaluation of risk of malignancy index based on serum CA 125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br. J. Obstet. Gynaecol. 103 (1996) 826-831
9. Tingulstad S., Hagen B., Skjeldestad F.E., Halvorsen T., Nustad K., and Onsrud M. The risk of malignancy index to evaluate potential ovarian cancers in local hospitals. Br. J. Obstet. Gynaecol. 93 (1999) 448-452
10. Davis P.A., Jacobs I., Woolas R., Fish A., and Oram D. The adnexal mass: benign or malignant? Evaluation of risk of malignancy index. Br. J. Obstet. Gynaecol. 100 (1993) 927-931
11. Morgante G., Marca A.I., Ditto A., and Leo V.D. Comparison of two malignancy risk indices based on serum CA 125, ultrasound score, and menopausal status in the diagnosis of ovarian masses. Br. J. Obstet. Gynaecol. 106 (1999) 524-527
12. Hagen B., Tingulstad S., Onsrud M., Moen M., Kiserud T., Eik-Nes S., et al. Preoperative identification of malignancy among women with a pelvic mass. Evaluation of a risk index based on ultrasound findings, CA 125 in serum and menopausal status. Tidsskr. Nor. Laegeforen. 115 (1995) 820-822
13. Andersen E.S., Knudsen A., Rix P., and Johansen B. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol. Oncol. 90 (2003) 109-112
14. Clemmensen I., Petersen L.C., and Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur. J. Biochem. 156 (1986) 327-333
15. Danø K., Andreasen P.A., Grøndahl-Hansen J., Kristensen P., Nielsen L.S., and Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44 (1985) 139-266
16. Høgdall C.K., Christensen L., and Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer 72 (1993) 2415-2422
17. Høgdall C.K., Høgdall E.V., Hørding U., Clemmensen I., Nørgaard-Pedersen B., and Toftager-Larsen K. Preoperative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand. J. Clin. Lab. Invest. 53 (1993) 741-746
18. Høgdall C.K., Høgdall E.V., Hørding U., Daugaard S., Clemmensen I., Nørgaard-Pedersen B., et al. Plasma tetranectin and ovarian neoplasms. Gynecol. Oncol. 43 (1991) 103-107
19. Høgdall C.K., Mogensen O., Tabor A., Mogensen B., Jakobsen A.K., Nørgaard-Pedersen B., et al. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol. Oncol. 56 (1995) 22-28
20. Høgdall E.V., Høgdall C.K., Tingulstad S., Hagen B., Nustad K., Xu F.J., et al. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int. J. Cancer 89 (2000) 519-523
21. Begum F.D., Høgdall C.K., Kjaer S.K., Christensen L., Blaakaer J., Bock J.E., et al. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res. 24 3b (2004) 1981-1985 [May-Jun]
22. Høgdall E.V., Kjaer S.K., Blaakaer J., Christensen L., Glud E., Vuust J., et al. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study. Gynecol. Oncol. 100 1 (2006) 76-82 [Jan; Electronic publication 2005 Sep 23]
23. Høgdall E.V., Christensen L., Kjaer S.K., Blaakaer J., Bock J.E., Glud E., et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98 (2003) 66-73
24. Høgdall E.V.S., Høgdall C.K., Christensen L., Glud E., Blaakaer J., Bock J.E., et al. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res. 22 (2002) 1859-1864
25. Høgdall E.V., Høgdall C.K., Blaakaer J., Christensen L., Bock J.E., Vuust J., et al. K-ras alterations in Danish ovarian tumour patients. From the Danish "MALOVA" ovarian cancer study. Gynecol. Oncol. 89 (2003) 31-36
26. Begum F.D., Høgdall C.K., Kjaer S.K., Blaakaer J., Christensen L., Ryan A., et al. Distribution of microsatellite instability in Danish ovarian tumor patients and the prognostic value in ovarian cancer patients. Oncol. Res. 17 (2008) 43-49
27. Sheperd J.H. Revised FIGO staging for gynaecological cancer. Br. J. Obstet. Gynecol. 96 (1989) 889-892
28. Serov S.F., Scully R.E., and Sobin L.H. International histological classification of tumors. No 9. Histological typing of ovarian tumors (1973), World Health Organization, Geneva, Switzerland
29. Clemmensen I., Lund L.R., Christensen L., and Andreasen P.A. A tetranectin-related protein is produced and deposited in extracellular matrix by human embryonal fibroblasts. Eur. J. Biochem. 195 (1991) 735-741
30. Bast Jr. R.C., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309 (1983) 883-887
31. Jacobs I., and Bast Jr. R.C. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4 (1989) 1-12
32. McGuckin M.A., Layton G.T., Bailey M.J., Hurst T., Khoo S.K., and Ward B.G. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma - comparison with CA125. Gynecol. Oncol. 37 (1990) 165-171
33. Vasilev S.A., Schlaerth J.B., Campeau J., and Morrow C.P. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet. Gynecol. 71 (1988) 751-756
34. Chen D.X., Schwartz P.E., Li X.G., and Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet. Gynecol. 72 (1988) 23-27
35. Einhorn N., Bast Jr. R.C., Knapp R.C., Tjernberg B., and Zurawski Jr. V.R. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 67 (1986) 414-416
36. Malkasian Jr. G.D., Knapp R.C., Lavin P.T., Zurawski Jr. V.R., Podratz K.C., Stanhope C.R., et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am. J. Obstet. Gynecol. 159 (1988) 341-346
37. Patsner B., and Mann W.J. The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am. J. Obstet. Gynecol. 159 (1988) 873-876
38. Soper J.T., Hunter V.J., Daly L., Tanner M., Creasman W.T., and Bast Jr. R.C. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet. Gynecol. 75 2 (1990) 249-254
39. Skates S.J., Xu F.J., Yu Y.H., Sjövall K., Einhorn N., Chang Y., et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76 10 Suppl (1995) 2004-2010
40. The Surveillance Program, Division of Cancer Prevention and Control. Cancer statistics review 1973-1987 (1988), National Cancer Institute, Washington DC
41. Gilis C.R., Hole D.J., Still R.M., Davis J., and Kaye S.B. Medical audit, cancer registration, and survival in ovarian cancer. Lancet 337 (1991) 611-612
42. Jacobs I.J., Rivera H., Oram D.H., and Base R.C. Differential diagnosis of ovarian cancer with tumor markers CA 125, CA 15-3, and TAG 72.3. Br. J. Obstet. Gynecol. 100 (1993) 1120-1124